RBC Capital raised the firm’s price target on Johnson & Johnson to $265 from $255 and keeps an Outperform rating on the shares after its Q1 earnings beat and guidance raise. The firm says it is encouraged with JNJ‘s progress in Q1 supported by strong Tremfya uptake, successful ICOTYDE adoption, steady MedTech end-markets, and a strong portfolio/pipeline that should position the company towards its goal of double-digit growth through the end of the decade.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Protagonist Therapeutics price target raised to $121 from $110 at Truist
- Johnson & Johnson price target raised to $250 from $220 at Stifel
- Johnson & Johnson price target raised to $255 from $234 at Barclays
- Johnson & Johnson Bets Big on Next-Gen Growth
- 3 Dividend Aristocrat Stocks Set to Reign With 15%+ Returns, 04/14/2026